Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 0.06 GBp
Change Today -0.005 / -8.33%
Volume 7.8M
PYC On Other Exchanges
As of 11:30 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

physiomics plc (PYC) Snapshot

0.06 GBp
Previous Close
0.06 GBp
Day High
0.06 GBp
Day Low
0.06 GBp
52 Week High
10/7/14 - 0.18 GBp
52 Week Low
07/20/15 - 0.05 GBp
Market Cap
Average Volume 10 Days
-0.0002 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for PHYSIOMICS PLC (PYC)

Related News

No related news articles were found.

physiomics plc (PYC) Related Businessweek News

No Related Businessweek News Found

physiomics plc (PYC) Details

Physiomics Plc provides outsourced systems and computational biology services to pharmaceutical companies in the United Kingdom, the United States, and European Union. The company’s services include Virtual Tumour, which is used to optimize the dosing and scheduling of oncology drugs in pre-clinical trials; and Virtual Tumour Preclinical that provides a rationale for designing a schedule, and allows to prioritize the drug combinations; and services to predict cardiac toxicity. It also offers model based drug development services, including population PKPD analysis of clinical data, back-translational analysis, optimal design of future studies, and preparation for due diligence. In addition, the company offers target validation and lead selection services. Further, it is developing Virtual Tumor Clinical to predict optimal regimens for human clinical trials; cardiac tox prediction service to predict unwanted toxic side effects of drug candidates early on in the drug discovery process; and drug combinations database for researchers and clinicians to access literature data on pre-clinical and clinical regimens and their effects. The company has collaboration and partnership agreements with Eli Lilly, Sareum, Institute of Cancer Research, Cancer Research Technology, Cyclacel Pharmaceutical, ValiRx, Phramacometrics, Institute of Life Science at Swansea University, TEMPO, and Bayer Technology Services GmbH. Physiomics Plc is based in Oxford, the United Kingdom.

5 Employees
Last Reported Date: 11/20/14

physiomics plc (PYC) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: 108.6K GBP
Chief Operating Officer, Director and Member ...
Total Annual Compensation: 58.5K GBP
Compensation as of Fiscal Year 2014.

physiomics plc (PYC) Key Developments

Physiomics plc Appoints Mark Middleton to Scientific Advisory Board

Physiomics plc announced that it has appointed Professor Mark Middleton to its Scientific Advisory Board. Professor Middleton is Professor of Experimental Cancer Medicine in the Department of Oncology of the University of Oxford. He is an eminent clinician with highly relevant clinical experience. Mark is the Lead Cancer Clinician for the Oxford University Hospitals NHS Trust and deputy director of the Cancer Research UK Oxford Centre. He directs the EPCTU and the Cancer Theme of the NIHR Biomedical Research Centre.

Physiomics plc Announces Unaudited Earnings Results for the Half Year Ended December 31, 2014

Physiomics plc announced unaudited earnings results for the half year ended December 31, 2014. For the period, the company's revenue was £0.13 million compared with £0.13 million a year ago. Operating loss was £0.24 million compared with £0.22 million a year ago. Loss before taxation was £0.24 million compared with £0.21 million a year ago. Loss for the period attributable to equity shareholders was £0.22 million or 0.011 pence per basic and diluted share compared with £0.2 million or 0.013 pence per basic and diluted share a year ago. Net cash generated from operating activities was £0.3 million compared with £0.27 million a year ago.

Physiomics plc Signs Contract for Developing Virtual Tumour Clinical with Merck Serono

Physiomics plc announced that it has signed its first contract for developing Virtual Tumour Clinical with a global pharmaceutical company. The client is Merck Serono. Revenue from the contract will fall in the 2014/2015 and 2015/2016 financial years and is in the region of the total value of all of Physiomics 2013/2014 sales.  The contract runs for 14 months and involves Physiomics scientists working closely with Merck Serono scientists to develop and calibrate a model that can predict optimal combination partners for both marketed and pipeline drugs. The parties will focus on making predictions of clinical outcomes for different dosing and scheduling regimens which, if convincing, could have an impact on final clinical trial design of investigational products, and potential drug combinations. In addition, the parties will look at whether the results can be used to suggest new cancer indications for drug combinations of interest.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PYC:LN 0.06 GBp -0.005

PYC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PYC.
View Industry Companies

Industry Analysis


Industry Average

Valuation PYC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.0x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHYSIOMICS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at